Similar articles for PMID: 28920889

Year	Number of Results
2005	1
2006	1
2007	2
2009	3
2010	2
2011	6
2012	6
2013	3
2014	10
2015	6
2016	9
2017	9
2018	16
2019	15
2020	16
2021	5
2022	5
2023	4
2024	0

1

Therapies targeting DNA and RNA in Huntington's disease.

Wild EJ, Tabrizi SJ. Wild EJ, et al. Lancet Neurol. 2017 Oct;16(10):837-847. doi: 10.1016/S1474-4422(17)30280-6. Epub 2017 Sep 12. Lancet Neurol. 2017. PMID: 28920889 Free PMC article. Review.

2

Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease.

Tabrizi SJ, Ghosh R, Leavitt BR. Tabrizi SJ, et al. Neuron. 2019 Mar 6;101(5):801-819. doi: 10.1016/j.neuron.2019.01.039. Neuron. 2019. PMID: 30844400 Free article. Review.

3

Therapeutic strategies for Huntington's disease.

Estevez-Fraga C, Flower MD, Tabrizi SJ. Estevez-Fraga C, et al. Curr Opin Neurol. 2020 Aug;33(4):508-518. doi: 10.1097/WCO.0000000000000835. Curr Opin Neurol. 2020. PMID: 32657893 Review.

4

Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities.

Tabrizi SJ, Estevez-Fraga C, van Roon-Mom WMC, Flower MD, Scahill RI, Wild EJ, Muñoz-Sanjuan I, Sampaio C, Rosser AE, Leavitt BR. Tabrizi SJ, et al. Lancet Neurol. 2022 Jul;21(7):645-658. doi: 10.1016/S1474-4422(22)00121-1. Lancet Neurol. 2022. PMID: 35716694 Free PMC article. Review.

5

Translating Antisense Technology into a Treatment for Huntington's Disease.

Lane RM, Smith A, Baumann T, Gleichmann M, Norris D, Bennett CF, Kordasiewicz H. Lane RM, et al. Methods Mol Biol. 2018;1780:497-523. doi: 10.1007/978-1-4939-7825-0_23. Methods Mol Biol. 2018. PMID: 29856033 Review.

6

Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington's Disease.

Imbert M, Blandel F, Leumann C, Garcia L, Goyenvalle A. Imbert M, et al. Nucleic Acid Ther. 2019 Oct;29(5):256-265. doi: 10.1089/nat.2018.0775. Epub 2019 Jun 11. Nucleic Acid Ther. 2019. PMID: 31184975

7

Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies.

Wright GEB, Black HF, Collins JA, Gall-Duncan T, Caron NS, Pearson CE, Hayden MR. Wright GEB, et al. Lancet Neurol. 2020 Nov;19(11):930-939. doi: 10.1016/S1474-4422(20)30343-4. Lancet Neurol. 2020. PMID: 33098802 Review.

8

Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.

Miniarikova J, Evers MM, Konstantinova P. Miniarikova J, et al. Mol Ther. 2018 Apr 4;26(4):947-962. doi: 10.1016/j.ymthe.2018.02.002. Epub 2018 Feb 8. Mol Ther. 2018. PMID: 29503201 Free PMC article. Review.

9

Huntingtin-lowering strategies in Huntington's disease: antisense oligonucleotides, small RNAs, and gene editing.

Aronin N, DiFiglia M. Aronin N, et al. Mov Disord. 2014 Sep 15;29(11):1455-61. doi: 10.1002/mds.26020. Epub 2014 Aug 27. Mov Disord. 2014. PMID: 25164989 Review.

10

Therapeutic Update on Huntington's Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies.

Dash D, Mestre TA. Dash D, et al. Neurotherapeutics. 2020 Oct;17(4):1645-1659. doi: 10.1007/s13311-020-00891-w. Neurotherapeutics. 2020. PMID: 32705582 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

107 results

Results by year